At BioCrea we turn concepts into drug candidates, creating first-in-class drugs to treat debilitating central nervous system (CNS) diseases. Through the combination of our unique discovery platforms, the use of patient-derived models and clinical data together with an experienced, visionary team, the company discovers and develops new drug candidates for pharmaceutical and biotechnology partners.
April 23, 2014
BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today provided an update on two unique proprietary small molecule programs: Long-term acting GABAA positive allosteric modulators (LT GABAA PAMs) to treat epilepsy plus autism; and NMDA receptor 2B (NR2B) negative allosteric modulators (NAMs) to treat depression. The pathways of both therapy approaches have been established in proof-of-concept trials conducted with similar compounds and they both show great potential to overcome limitations of their predecessors. BioCrea has initiated an outlicensing program to expedite the progression of these assets into the clinic.
January 09, 2014
BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist validated through pharma partnerships, announced today that the Epilepsy Foundation (Maryland, US) has presented the Epilepsy Innovation Seal of Excellence Award to BioCrea in recognition of the creation of the new anti-seizure platform, Novel Long Term Effective GABAA PAMs (LT GABAA PAM), to treat refractory epilepsy.